KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12.
The factors that initiate and maintain the abnormal hematopoietic clone in the myelo-dysplastic syndromes (MDS) remain largely unknown. We describe a patient with MDS associated with an abnormal karyotype, 46,XY,t(5;12)(q31;p12). According to the FAB cooperative group classification, the patient was classified as chronic myelomonocytic leukemia. Because of the particular chromosomal translocation, the structure-function relationship of three genes relevant to the translocation breakpoints, CSF2, FMS, and KRAS2, was studied in bone marrow and peripheral blood lymphocytes in this patient. No major structural alterations were observed at these three genetic loci. Although the levels of expression of the CSF2 and FMS genes remained unaltered, the KRAS2 oncogene was overexpressed approximately six-fold in bone marrow cells from the MDS patient compared with normal donors. We postulate that the RAS oncogene activation may be instrumental in the genesis of MDS.
Srivastava
A
A
Department of Medicine, Indiana University School of Medicine, Indianapolis 46223.
Boswell
H S
HS
Heerema
N A
NA
Nahreini
P
P
Lauer
R C
RC
Antony
A C
AC
Hoffman
R
R
Tricot
G J
GJ
D000328:Adult; D015139:Blotting, Southern; D002453:Cell Cycle; D002871:Chromosome Banding; D002881:Chromosomes, Human, Pair 12; D002895:Chromosomes, Human, Pair 5; D004247:DNA / Q000235:genetics; D005819:Genetic Markers; D006801:Humans; D007621:Karyotyping; D008297:Male; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000473:pathology; D009857:Oncogenes; D014178:Translocation, Genetic
D005819:Genetic Markers; D004247:DNA